RXST LOSS ALERT: RxSight, Inc. Investors with Losses are Reminded of the September 22 Class Action Deadline – Contact BFA Law (NASDAQ:RXST)

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a significant decline in stock price, dropping approximately 38% from $26.12 to $16.21 on April 3, 2025, after cutting its 2025 revenue forecast due to a market softening noted in the second half of 2024 [5]. - Following another revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell again by about 38%, from $12.79 to $7.95 on July 9, 2025 [6].